Meeting
2011 ASCO Annual Meeting
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
Authors
B. Grana
Vall d'Hebron University Hospital, Barcelona, Spain
B. Grana , H. A. Burris III, J. Rodon Ahnert , A. R. Abdul Razak , M. J. De Jonge , F. Eskens , L. L. Siu , Q. C. Ru , N. F. Homji , D. Demanse , E. Di Tomaso , J. G. C. E. Cosaert , C. Quadt , J. Baselga , J. C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
PI3-Akt-mTOR Pathway
Clinical Trial Registration Number
NCT01068483
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3043)
Abstract #
3043
Poster Bd #
11H
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
First Author: Maliha Nusrat
Poster
2015 ASCO Annual Meeting
Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.
First Author: Sarina Anne Piha-Paul
Poster
2015 Gastrointestinal Cancers Symposium
Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors.
First Author: Sarina Anne Piha-Paul
Poster
2013 ASCO Annual Meeting
PIKHER2: A phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer.
First Author: Anthony Goncalves